Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease

NCT01690390 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Icotinib of routine dose
DRUG: Icotinib of high dose

Sponsor

Betta Pharmaceuticals Co., Ltd.